A COMPARISON OF ZIDOVUDINE, DIDANOSINE, ZALCITABINE AND NO ANTIRETROVIRAL THERAPY IN PATIENTS WITH ADVANCED HIV DISEASE

被引：9

作者：

TORRES, RA

BARR, MR

MCINTYRE, KI

THORNTON, JR

SHAY, WM

FELDMAN, RD

GEORGE, NJ

BRITTON, DJ

机构：

[1] St Vincent's Hospital, Medical Center of New York

[2] AIDS Institute, New York State Department of Health, New York, NY

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 1995年 / 6卷 / 01期

关键词：

HIV; ANTIRETROVIRAL; ZIDOVUDINE; DIDANOSINE; ZALCITABINE;

D O I：

10.1177/095646249500600105

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Three nucleoside analogues, zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC), are approved for use in the treatment of patients with HIV infection. This retrospective study compares the 3 drugs and examines the overall utility of antiretroviral therapy by way of comparisons to a no treatment (No Rx) group in patients with advanced HIV disease. Patients with advanced HIV disease were enrolled in didanosine (August 1989-December 1990) or zalcitabine (October 1990-February 1992) expanded access programmes; continued on zidovudine treatment despite fulfilling criteria for zidovudine failure or intolerance; or maintained on no antiretroviral treatment. Statistical analysis revealed that patients on nucleoside analogue therapy had fewer opportunistic infections (P=0.001) than those who received no antiretroviral treatment. The Kaplan-Meier 12-month estimate of survival was significantly longer among patients who switched from zidovudine to zalcitabine but not among patients who switched to didanosine, when compared to the other 2 groups (P=0.05).

引用

页码：19 / 26

页数：8

共 20 条

[1]

Merigon T.S., Skowron G., Bozzette S., Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections, Ann Intern Med, 110, pp. 189-194, (1989)

[2]

Yarchoan R., Thomas R.V., Allain J., Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine, Lancet, i, pp. 76-87, (1987)

[3]

Yarchoan R., Mitsuya H., Thomas R.V., Et al., In vivo activity against HIV and favorable toxicity of 2,3′-dideoxyinosine, Science, 245, pp. 412-415, (1989)

[4]

Cooley T.P., Kunches L.M., Saunders C.A., Et al., Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A Phase I trial, N Engl J Med, 322, pp. 1333-1340, (1990)

[5]

Lambert J.S., Seidlin M., Reichman R.C., Et al., 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex, Lancet, 336, pp. 526-529, (1990)

[6]

Kahn J.O., Lagakos S.W., Richman D.D., A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus injection, N Engl J Med, 327, pp. 581-587, (1992)

[7]

Dolin R., Amato M., Fischi M., Et al., Ninth International Conference on AIDS, Efficacy of didanosine (ddI) versus zidovudine (ZDV) in patients with no or ≤ 16 weeks of prior ZDV therapy (abstract WS-B24–1), (1993)

[8]

2400 W. Lloyd Expressway, R-22, Evansville, IN 47721–1001. VIDEX package insert

[9]

Follansbee S., Drew L., Pollard R., Et al., The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naïve patients with advanced HIV disease, A randomized double-blind comparative trial (ACTG 114: N3300) (abstract PO-B26–2113). Ninth, (1993)

[10]

Fischi M.A., Olson R.M., Rollonsbee S.E., Et al., Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 infection Who Received Previous Zidovudine Therapy, Ann Intern Med, 118, pp. 762-769, (1993)

← 1 2 →